Zhang et al. found that ACE2 was positively correlated with the immune-promoting/immunosuppressive cell ratio in a variety of cancers and was associated with the anti-PD-1/PD-L1/CTLA-4 immunotherapy response. Here, CTLA4 is linked to cancer.